← All trials
NCT04167514
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2019
- Primary completion
- Nov 30, 2023
- Completion date
- Nov 30, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 122
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CSL BehringLead sponsor
- CSL BehringStudy director
- National Institutes of Health (NIH)Collaborator
- National Cancer Institute (NCI)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.